Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.10 USD

41.10
318,984

-0.08 (-0.19%)

Updated Aug 14, 2024 10:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up

J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.

Best Income Stocks to Buy for November 15th

LADR, GSK, ATCO, and FRG made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 15, 2021.

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion

Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down

AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.

Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3

Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.

Best Income Stocks to Buy for November 11th

BX, COP, and GSK made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 11, 2021.

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

Is (GSK) Outperforming Other Medical Stocks This Year?

Bayer's (BAYRY) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Bayer's (BAYRY) earnings in the third quarter of 2021 beat estimates. Revenues surge year over year.

Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up

Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.

Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View

Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Company News for Oct 28, 2021

Companies in The News Are: KO,MCD,GSK,IP

Indrajit Bandyopadhyay headshot

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q3

Glaxo (GSK) beats earnings as well as revenues estimates in the third quarter of 2021. Stock up.

Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.

The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline

The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline

Sheraz Mian headshot

Top Analyst Reports for Tesla, Johnson & Johnson & PayPal

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Johnson & Johnson (JNJ), and PayPal Holdings, Inc. (PYPL).

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.